Colgate-Palmolive Company Revenue & Financials

Colgate-Palmolive generated $20.22 billion in net revenues for the fiscal year 2024, representing a 2.1% increase in organic net revenues (which excludes the impact of foreign exchange translation and acquisitions/divestitures) and a 0.5% decline in reported net revenues, a performance that was driven by a 3.5% contribution from pricing and mix, which more than offset a 1.4% decline in underlying global volumes, highlighting the company's successful execution of its pricing-led growth strategy during the 2021-2024 inflationary cycle, but also signaling the exhaustion of pricing power in the Home Care segment as consumers began to trade down to private-label alternatives in response to cumulative price increases of over 18% on core SKUs. The company's gross profit reached $12.1 billion in FY2024, representing a gross margin of 60.0%, a 40-basis-point decline from FY2023, driven by severe input cost inflation, particularly in HDPE resin (which increased by 22% year-over-year) and palm oil derivatives, as well as the unfavorable impact of emerging market currency devaluations, which increased the local-currency cost of imported raw materials. Despite the gross margin compression, the company's operating income reached $4.8 billion in FY2024, representing an operating margin of 23.9%, a 30-basis-point improvement from FY2023, driven by rigorous overhead cost control, a 6% reduction in discretionary marketing spend in the second half of the year, and the realization of $300 million in savings from the company's ongoing 'Global Productivity and Efficiency' program, which includes supply chain automation, SKU rationalization (the company eliminated over 1,200 underperforming SKUs in FY2024 to reduce manufacturing complexity), and the consolidation of back-office functions. Net income for FY2024 was $3.53 billion, or $4.15 per diluted share, representing a 4.8% increase from FY2023, driven by the operating income growth and a lower effective tax rate (21.2% in FY2024 vs. 22.5% in FY2023), partially offset by a $60 million increase in net interest expense due to higher global interest rates on the company's $10 billion long-term debt portfolio. The company's free cash flow was $3.8 billion in FY2024, a 2% decline from FY2023, driven by a $200 million increase in working capital requirements (primarily due to higher inventory levels to hedge against resin supply chain disruptions and the impact of hyperinflationary accounting in Argentina) and a $750 million capital expenditure program, which was focused on capacity expansion for Hill's Pet Nutrition and automation upgrades in North America and Europe. The company's return on invested capital (ROIC) was 28.5% in FY2024, well above its weighted average cost of capital (WACC) of 8.5% and the industry average of 14.2%, demonstrating the underlying profitability and capital efficiency of the business. The company's capital allocation strategy in FY2024 was highly shareholder-friendly, returning over $2.8 billion to shareholders through $1.6 billion in dividends (representing a 1.9% dividend yield and a 61-year streak of consecutive dividend increases, making it one of the longest-running Dividend Kings in the S&P 500) and $1.2 billion in share repurchases (under a $3 billion board-authorized buyback program), while simultaneously funding $1.4 billion in strategic acquisitions (including the final earn-out payments for the Filorga acquisition) and $100 million in debt reduction. The company's balance sheet remains strong, with a net debt-to-EBITDA ratio of 2.1x at the end of FY2024, well within its target range of 1.5x-2.5x, and $2.5 billion in cash and cash equivalents, providing ample liquidity to fund ongoing operations, M&A activity, and shareholder returns. The company's financial performance in FY2024 was heavily influenced by the macroeconomic environment, particularly the severe currency headwinds in emerging markets (which reduced reported revenue by $1.3 billion) and the unprecedented spike in HDPE resin prices, which forced the company to absorb significant unhedged costs in the second half of the year. Looking ahead to FY2025, the company has guided for mid-single-digit organic net revenue growth (4-6%), driven by a return to positive volume growth (1-2%) and a modest 3-4% contribution from pricing, as the company deliberately rolls back prices on core Home Care SKUs to stimulate volume recovery, a strategy that is expected to compress gross margins by an additional 40-60 basis points in the first half of FY2025 before stabilizing as resin hedging costs normalize and productivity savings offset input cost inflation. The company's financial narrative is ultimately one of resilience and adaptability, demonstrating the ability to navigate severe macroeconomic headwinds, commodity price shocks, and currency volatility while maintaining strong profitability, generating robust free cash flow, and executing a disciplined capital allocation strategy that rewards shareholders and funds long-term growth.